DNER and ovarian carcinoma: Zhang et al. have suggested a novel approach, wherein the combined use of phase separation of BRD4 droplets and aurora kinase inhibitors effectively counteracts the antagonistic impact of BET bromodomain inhibitors, thereby targeting and eradicating JQ1-resistant ovarian cancer cells 153.